Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      WITHDRAWN
      Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
      Description

      This phase II trial studies how well enasidenib works in treating in patients with acute myeloid leukemia with an IDH2 gene mutation that has come back or has not responded to treatment. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. In this study we are investing if enasidenib can be used as maintenance therapy post salvage induction chemotherapy.

      Conditions
      Blasts Under 5 Percent of Peripheral Blood White CellsBone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment LevelIDH2 Gene MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
      Talk to us
      WITHDRAWN
      Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
      Description

      This phase Ib/II trial studies side effects and best dose of inotuzumab ozogamicin and how well it works when given together with vincristine sulfate liposome in treating patients with CD22 positive (+) B-cell acute lymphoblastic leukemia that has come back or dose not respond to treatment. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22+ cancer cells in a targeted way and delivers ozogamicin to kill them. Drugs used in chemotherapy, such as vincristine sulfate liposome, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin and vincristine sulfate liposome together may work better in treating patients with CD22+ B-cell acute lymphoblastic leukemia compared to giving inotuzumab ozogamicin or vincristine sulfate liposome alone.

      Conditions
      Allogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White CellsCD22 PositiveLymphoblasts 20 Percent or More of Bone Marrow Nucleated CellsLymphoblasts 20 Percent or More of Peripheral Blood White CellsRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
      Talk to us
      RECRUITING
      Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
      Description

      This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

      Conditions
      BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Peripheral Blood White CellsBlasts Under 20 Percent of Bone Marrow Nucleated CellsChronic Eosinophilic Leukemia, Not Otherwise SpecifiedEosinophiliaHepatomegalyHypereosinophilic SyndromeJAK2 Gene MutationSplenomegalyTEL-JAK2 Fusion Protein Expression
      Talk to us